Both companies have made their products available on Azure, and Curoverse is collaborating with Microsoft on benchmarking tools for analysis pipelines.
Icon will use its data management capabilities and clinical trials expertise to validate clinical data from the 70,000 participating patients and their families.
The companies are combining their respective products to provide a solution that covers genetic testing from sample prep to clinical reports.
The company hopes to begin marketing the so-called RealTime Oncology calculator, first in the US and then more broadly, starting in June.
The company is testing a database solution that will help clinical researchers store, manage, and analyze variant information ahead of full launch this quarter.
Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.
Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.
In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.
President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.
This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions.